Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

18.47 +0.13 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 Next >
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces CFO Transition
Executive Search Initiated for CFO Replacement 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
Conference Call Scheduled for November 8, 2023, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
Conference Call Scheduled for May 10, 2023, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Amendment to Credit Agreement
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Proposed Public Offering of Common Stock
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022
From ADMA Biologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.